Showing results (91-100 of 136) with videos related to

Sort By:
Pageof 14
Carcinogenesis|July 4, 2014
Potentially functional variants in the core nucleotide excision repair genes predict survival in Japanese gastric cancer patientsYangkai Li, Zhensheng Liu, Hongliang Liu, et al.
Cancer Science|September 15, 2022
Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practiceHanae Ida, Takafumi Koyama, Takaaki Mizuno, et al.
Cancer Discovery|June 27, 2023
Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II StudyTakafumi Koyama, Toshio Shimizu, Yuki Kojima, et al.
Frontiers in Oncology|December 13, 2021
Clinical Utility of Circulating Tumor DNA in Advanced Rare CancersHitomi Sumiyoshi Okuma, Kan Yonemori, Yuki Kojima, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|June 24, 2024
Folate Receptor Alpha Expression and the Tumor Immune Microenvironment in Patients with Cervical CancerShu Yazaki, Yohei Chiba, Yuki Kojima, et al.
Breast Cancer Research and Treatment|June 22, 2026
Clinical implications of discordance in HER2 reassessment from HercepTest to 4B5 in metastatic breast cancerYuhei Yamaguchi, Mai Hoshino, Tatsunori Shimoi, et al.
Oncology|April 11, 2022
Poor Treatment Outcomes with Second-Line Chemotherapy in Advanced Synovial SarcomaYuki Kojima, Tatsunori Shimoi, Takuji Seo, et al.
Oncology Letters|August 18, 2020
HER3 protein expression as a risk factor for post-operative recurrence in patients with early-stage adenocarcinoma and adenosquamous carcinoma of the cervixTakaaki Mizuno, Yuki Kojima, Kan Yonemori, et al.
Oncology Letters|October 30, 2020
Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancerTakaaki Mizuno, Yuki Kojima, Kan Yonemori, et al.
Virchows Archiv : an International Journal of Pathology|September 5, 2023
Discordance in PD-L1 expression using 22C3 and SP142 assays between primary and metastatic triple-negative breast cancerJun Miyakoshi, Shu Yazaki, Tatsunori Shimoi, et al.
Pageof 14